| Host: |
Rabbit |
| Applications: |
IF |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Phospho-BRCA1-S988 is suitable for use in Immunofluorescence research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
IF/ICC 1:50-1:200 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
BRCA1 |
| Gene ID: |
672 |
| Uniprot ID: |
BRCA1_HUMAN |
| Immunogen: |
A synthetic phosphorylated peptide around S988 of human BRCA1 (NP_009225.1). |
| Immunogen Sequence: |
IKSFV |
| Tissue Specificity | Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines. |
| Post Translational Modifications | Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR. Phosphorylation at Ser-988 by CHEK2 regulates mitotic spindle assembly. Phosphorylation by AURKA regulates centrosomal microtubule nucleation. Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation. |
| Function | E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Required for FANCD2 targeting to sites of DNA damage. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator. |
| Protein Name | Breast Cancer Type 1 Susceptibility ProteinRing Finger Protein 53Ring-Type E3 Ubiquitin Transferase Brca1 |
| Database Links | Reactome: R-HSA-1221632Reactome: R-HSA-3108214Reactome: R-HSA-5685938Reactome: R-HSA-5685942Reactome: R-HSA-5689901Reactome: R-HSA-5693554Reactome: R-HSA-5693565Reactome: R-HSA-5693568Reactome: R-HSA-5693571Reactome: R-HSA-5693579Reactome: R-HSA-5693607Reactome: R-HSA-5693616Reactome: R-HSA-6796648Reactome: R-HSA-6804756Reactome: R-HSA-69473Reactome: R-HSA-8951664Reactome: R-HSA-8953750Reactome: R-HSA-912446Reactome: R-HSA-9663199Reactome: R-HSA-9699150Reactome: R-HSA-9701192Reactome: R-HSA-9704331Reactome: R-HSA-9704646Reactome: R-HSA-9709570Reactome: R-HSA-9709603Reactome: R-HSA-9755511 |
| Cellular Localisation | NucleusChromosomeCytoplasmLocalizes At Sites Of Dna Damage At Double-Strand Breaks (Dsbs)Recruitment To Dna Damage Sites Is Mediated By Abraxas1 And The Brca1-A ComplexTranslocated To The Cytoplasm During Uv-Induced ApoptosisIsoform 3: CytoplasmIsoform 5: Cytoplasm |
| Alternative Antibody Names | Anti-Breast Cancer Type 1 Susceptibility Protein antibodyAnti-Ring Finger Protein 53 antibodyAnti-Ring-Type E3 Ubiquitin Transferase Brca1 antibodyAnti-BRCA1 antibodyAnti-RNF53 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
